All In Biotech

Drug Trial Radar · NCT05891483

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Sep 4, 2023

Primary completion

Jan 21, 2026

Study completion Jan 21, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • SHR-1905 InjectionDrug

    SHR-1905 Injection

  • SHR-1905 Placebo InjectionDrug

    SHR-1905 Placebo Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nasal polyp scores (NPS)Time frame: Baseline to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eye & Ent Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.